Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2- Advanced Breast Cancer.

Many breast cancers are driven by a specific signaling pathway called PI3K/AKT/mTOR. When standard hormone therapies stop working, doctors are developing new drugs that specifically block this pathway to help patients live longer. These new drugs are being designed to be more precise. Their goal is to have fewer side effects like high blood sugar.

The hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) subtype accounts for approximately 70% of all breast cancer cases. For years, the standard of care has relied on endocrine therapy (hormone-blocking treatments) combined with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). However, resistance to these treatments is inevitable. As the tumor evolves, it often activates the PI3K-AKT-mTOR signaling axis. This is a biological communication network that regulates cell growth, metabolism, and survival. It acts as a way to bypass the initial treatment.

A recent review by Lei et al. explores how new generations of drugs are moving away from blunt-force inhibition toward surgical precision. Instead of shutting down the entire pathway, researchers are developing agents that target specific "nodes" or mutated versions of these proteins.

The breakdown of endocrine-sensitive therapy

Current treatment protocols for advanced HR+/HER2– breast cancer typically begin with endocrine therapy and CDK4/6 inhibitors. While effective initially, this approach eventually fails as tumors develop resistance. The authors identify the PI3K-AKT-mTOR pathway as a central driver of this failure. Genetic alterations in this axis are found in roughly 40–50% of advanced cases. These include mutations in the PIK3CA gene, mutations in AKT1, or the loss of the tumor suppressor PTEN.

The failure of existing drugs often stems from a lack of specificity. Early attempts at pathway inhibition used "pan-PI3K" inhibitors. These drugs target all members of the PI3K family simultaneously. While these drugs can stop tumor growth, they act like a sledgehammer hitting a delicate circuit board. They disrupt essential metabolic and immune functions in healthy cells. This leads to severe toxicities. Common issues include significant hyperglycemia (high blood sugar) and gastrointestinal issues. These side effects often force patients to stop treatment before the tumor is adequately controlled.

Precision targeting the signaling cascade

To solve the toxicity problem, the research focuses on agents that target specific points in the signaling hierarchy shown in . The pathway functions like a relay race. A signal starts at a receptor, is passed to PI3K, then to AKT, and finally to mTOR. This last step triggers cell division.

The authors categorize emerging strategies into three main architectural approaches:

1. Isoform-specific inhibition: Rather than blocking all PI3K, newer drugs like alpelisib and inavolisib target the p110α subunit specifically. This is akin to disabling a specific faulty switch in a building. It avoids cutting the power to the entire city. Inavolisib goes a step further. It promotes the actual degradation (the breaking down) of the mutant protein.
2. Downstream node blockade: Drugs like capivasertib target AKT. This protein is positioned further down the signaling chain. By targeting a downstream component, these drugs can sometimes bypass upstream mutations. This helps when PI3K inhibitors become ineffective.
3. Dual and allosteric inhibition: New agents like gedatolisib attempt to block both PI3K and mTOR simultaneously. This prevents the cell from using "detours" to stay alive. Others are called allosteric inhibitors. These bind to unique, mutation-induced pockets on the protein. These pockets are not present in healthy cells. This theoretically spares normal tissue from harm.

Measuring clinical impact and survival

The effectiveness of these strategies is measured primarily through progression-free survival (mPFS). This is the length of time a patient lives without the disease getting worse.

The authors report several high-impact results from pivotal trials. In the SOLAR-1 trial, adding alpelisib to fulvestrant increased mPFS from 5.7 months to 11.0 months in patients with PIK3CA mutations. This nearly doubled the time patients lived without progression. Even more striking was the INAVO-120 trial. Inavolisib combined with palbociclib and fulvestrant yielded an mPFS of 15.0 months. This was much higher than the 7.3 months seen in the control arm.

Beyond mere survival, the paper emphasizes the "therapeutic window." This is the gap between a dose that kills the cancer and a dose that harms the patient. The authors note that inavolisib has demonstrated improved tolerability. For instance, while alpelisib is associated with hyperglycemia and rash in roughly 35% of patients, inavolisib may offer a better safety profile. Its ability to degrade mutant proteins is a key part of this advantage.

Identifying the remaining hurdles

Despite these advancements, several critical limitations remain. First, the complexity of resistance means a drug might be bypassed tomorrow. The authors point out that "on-target" resistance occurs. This happens when the tumor undergoes secondary mutations. These mutations change the shape of the protein. This prevents the drug from binding to its target.

Second, the reliability of diagnostic tools is a bottleneck. While liquid biopsies (blood tests looking for circulating tumor DNA, or ctDNA) are minimally invasive, they have limits. The authors report that sensitivity drops significantly when the ctDNA fraction is less than 1%. This makes it difficult to identify which patients truly possess the specific mutations needed for targeted therapy.

Finally, managing side effects remains a heavy burden. High blood sugar and skin rashes are persistent issues for almost all PI3K-targeted agents. While the authors mention that metformin and antihistamines can help, monitoring remains difficult. Constant medical oversight adds significant complexity to clinical practice.

The verdict: A move toward biomarker-driven sequencing

The transition from broad-spectrum chemotherapy to pathway-specific inhibition is underway. However, the era of "one size fits all" is over. For a clinician, the decision on which drug to use now depends on a patient's unique genomic signature.

If a patient has a PIK3CA mutation, the evidence supports isoform-specific inhibitors like inavolisib or alpelisib. If the resistance is driven by AKT1 or PTEN alterations, capivasertib is a primary candidate. The ultimate goal, as outlined in, is a personalized treatment algorithm.

In this model, genomic testing dictates the sequence of drugs. We are not yet at a "set and forget" solution. However, the roadmap for navigating endocrine resistance is becoming increasingly clear.

Figures from the paper